The modified Medical Research Council dyspnoea scale is a good indicator of health-related quality of life in patients with chronic obstructive pulmonary disease

Singapore Medical Journal

Volumn 54, Issue 6, 2013, Pages 321-327

  Hsu, Kun Yen ^a,c   Lin, Jr Rung ^a,b   Lin, Ming Shian ^c   Chen, Wei ^c   Chen, Yi Jen ^c   Yan, Yuan Horng ^d  

^a Pediatric Dentistry   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c Division of Pulmonary and Critical Care Medicine   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; Global initiative for chronic obstructive lung disease; Health related quality of life; Medical research council dyspnoea scale; Spirometry

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNOEA SCALE; OBSERVATIONAL STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SLEEP DISORDER; SPIROMETRY;

ADULT; AGED; AGED, 80 AND OVER; COUGH; CROSS-SECTIONAL STUDIES; DYSPNEA; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SPIROMETRY;

EID: 84879441114     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: 10.11622/smedj.2013125     Document Type: Article

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2010). Available at: http://www.goldcopd. org/uploads/users/files/GOLDReport_April112011.pdf. Accessed: August 31, 2011.
2. Marin JM, Cote CG, Diaz O, et al. Prognostic assessment in COPD: Health related quality of life and the BODE index. Respir Med 2011; 105:916-21.
3. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011; 105:57-66.
4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fiuticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89.
5. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-54.
6. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-73.
7. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823-32.
8. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680-5.
9. Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122:429-36.
10. Engstrom CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18:69-76.
11. Antonelli-Incalzi R, Imperiale C, Bellia V, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22:444-9.
12. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999; 116:1632-7.
13. Medinas Amoros M, Mas-Tous C, Renom-Sotorra F, et al. Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index. Chron Respir Dis 2009; 6:75-80.
14. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93:580-6.
15. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-6.
16. Oga T, Nishimura K, Tsukino M, et al. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007; 101:146-53.
17. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962-9.
18. Nizet TA, van den Elshout FJ, Heijdra YF, et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest 2005; 127:1904-10.
19. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182:325-31.
20. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-38.
21. Berglund E, Birath G, Bjure J, et al. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963; 173:185-92.
22. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airfiow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-7.
23. Wang KY, Chiang CH, Maa SH, Shau WY, Tarn YH. Psychometric assessment of the Chinese language version of the St. George's Respiratory Questionnaire in TWNese patients with bronchial asthma. J Formos Med Assoc 2001; 100:455-60.
24. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998; 46:1569-85.
25. Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the WHOQOL-BREF TWN version. J Formos Med Assoc 2002;101:342-51.
26. Agusti A. Thomas a. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3:478-81.
27. Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikas K. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med 2009; 103:650-60.
28. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009; 33:953-5.
29. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2:257-66.
30. Jones R, Ostrem A. Optimising pharmacological maintenance treatment for COPD in primary care. Prim Care Respir J 2011; 20:33-45.
31. Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63:768-74.
32. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-22.
33. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23:698-702.
34. Rutgers SR, ten Hacken NH, Koeter GH, Postma DS. Borg scores before and after challenge with adenosine 5'-monophosphate and methacholine in subjects with COPD and asthma. Eur Respir J 2000; 16:486-90.
35. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180:1189-95.
36. Annual report of tobacco, alcohol consumption investigation in TWN area. Taipei, TWN: Bureau of Tobacco and Alcohol Monopoly, TWN Provincial Government, 1993.